<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">34946282</PMID><DateCompleted><Year>2021</Year><Month>12</Month><Day>27</Day></DateCompleted><DateRevised><Year>2022</Year><Month>05</Month><Day>31</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1648-9144</ISSN><JournalIssue CitedMedium="Internet"><Volume>57</Volume><Issue>12</Issue><PubDate><Year>2021</Year><Month>Dec</Month><Day>07</Day></PubDate></JournalIssue><Title>Medicina (Kaunas, Lithuania)</Title><ISOAbbreviation>Medicina (Kaunas)</ISOAbbreviation></Journal><ArticleTitle><i>MOBP rs616147</i> Polymorphism and Risk of Amyotrophic Lateral Sclerosis in a Greek Population: A Case-Control Study.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1337</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/medicina57121337</ELocationID><Abstract><AbstractText><i>Background and Objectives</i>: To date, only one study has investigated the association between the <i>rs616147</i> polymorphism of the <i>Myelin-associated Oligodendrocyte Basic Protein (MOBP)</i> locus and Amyotrophic Lateral Sclerosis (ALS). <i>Materials and Methods</i>: A case-control study was performed. Patients with definite sporadic ALS were prospectively and consecutively recruited from the inpatient and outpatient clinics of the Neurology Department of the General University Hospital of Larissa, Central Greece. Community based, age and sex matched healthy individuals with a free personal and family history constituted the control group. <i>Results</i>: A total of 155 patients with definite sporadic ALS and an equal number of healthy controls were genotyped. The power of our sample size was slightly above 80% and <i>MOBP rs616147</i> was determined to be in Hardy-Weinberg Equilibrium among healthy participants (<i>p</i> = 1.00). According to the univariate analysis, there was no significant relationship between <i>rs616147</i> and ALS [log-additive OR = 0.85 (0.61, 1.19), over-dominant OR = 0.73 (0.46, 1.15), recessive OR = 1.02 (0.50, 2.09), dominant OR = 0.74 (0.47, 1.16), co-dominant OR<sub>1</sub> = 0.71 (0.44, 1.14) and co-dominant OR<sub>2</sub> = 0.88 (0.42, 1.84). Additionally, the effect of <i>rs616147</i> on the age of ALS onset was determined insignificant using both unadjusted and adjusted (sex, site of onset) cox-proportional models. Finally, <i>rs616147</i> was not related to the site of ALS onset. <i>Conclusions</i>: Our study is the first to report the absence of an association between <i>MOBP rs616147</i> and ALS among individuals of Greek ancestry. Additional, larger nationwide and multi-ethnic studies are warranted to shed light on the connection between <i>rs616147</i> and ALS.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Liampas</LastName><ForeName>Ioannis</ForeName><Initials>I</Initials><Identifier Source="ORCID">0000-0002-2958-5220</Identifier><AffiliationInfo><Affiliation>Laboratory of Neurogenetics, Department of Neurology, University Hospital of Larissa, Faculty of Medicine, University of Thessaly, 41100 Larissa, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Siokas</LastName><ForeName>Vasileios</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Laboratory of Neurogenetics, Department of Neurology, University Hospital of Larissa, Faculty of Medicine, University of Thessaly, 41100 Larissa, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aloizou</LastName><ForeName>Athina-Maria</ForeName><Initials>AM</Initials><Identifier Source="ORCID">0000-0001-9354-774X</Identifier><AffiliationInfo><Affiliation>Laboratory of Neurogenetics, Department of Neurology, University Hospital of Larissa, Faculty of Medicine, University of Thessaly, 41100 Larissa, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bakirtzis</LastName><ForeName>Christos</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-4737-3707</Identifier><AffiliationInfo><Affiliation>B' Department of Neurology, AHEPA University Hospital, Aristotle University of Thessaloniki, 54636 Thessaloniki, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsouris</LastName><ForeName>Zisis</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Laboratory of Neurogenetics, Department of Neurology, University Hospital of Larissa, Faculty of Medicine, University of Thessaly, 41100 Larissa, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nousia</LastName><ForeName>Anastasia</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Speech and Language Therapy, University of Ioannina, 45110 Ioannina, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nasios</LastName><ForeName>Grigorios</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0001-7495-6863</Identifier><AffiliationInfo><Affiliation>Department of Speech and Language Therapy, University of Ioannina, 45110 Ioannina, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Papadimitriou</LastName><ForeName>Dimitra</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Neurological Department, Henry Dunant Hospital Center, 11526 Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liakos</LastName><ForeName>Panagiotis</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Laboratory of Biochemistry, Faculty of Medicine, University of Thessaly, 41100 Larissa, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bogdanos</LastName><ForeName>Dimitrios P</ForeName><Initials>DP</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Clinical Immunology, University Hospital of Larissa, Faculty of Medicine, University of Thessaly, 41100 Larissa, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hadjigeorgiou</LastName><ForeName>Georgios M</ForeName><Initials>GM</Initials><AffiliationInfo><Affiliation>Laboratory of Neurogenetics, Department of Neurology, University Hospital of Larissa, Faculty of Medicine, University of Thessaly, 41100 Larissa, Greece.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Medical School, University of Cyprus, Nicosia 2029, Cyprus.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dardiotis</LastName><ForeName>Efthimios</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0003-2957-641X</Identifier><AffiliationInfo><Affiliation>Laboratory of Neurogenetics, Department of Neurology, University Hospital of Larissa, Faculty of Medicine, University of Thessaly, 41100 Larissa, Greece.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>5287</GrantID><Agency>University of Thessaly</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>12</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Medicina (Kaunas)</MedlineTA><NlmUniqueID>9425208</NlmUniqueID><ISSNLinking>1010-660X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C560487">MOBP protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009185">Myelin Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006115" MajorTopicYN="N" Type="Geographic">Greece</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009185" MajorTopicYN="N">Myelin Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009836" MajorTopicYN="N">Oligodendroglia</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011110" MajorTopicYN="N">Polymorphism, Genetic</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amyotrophic Lateral Sclerosis (ALS)</Keyword><Keyword MajorTopicYN="N">Motor Neuron Disease (MND)</Keyword><Keyword MajorTopicYN="N">Myelin-associated Oligodendrocyte Basic Protein (MOBP)</Keyword><Keyword MajorTopicYN="N">rs616147</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>11</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>11</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>12</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>12</Month><Day>24</Day><Hour>1</Hour><Minute>11</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>12</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>12</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34946282</ArticleId><ArticleId IdType="pmc">PMC8708438</ArticleId><ArticleId IdType="doi">10.3390/medicina57121337</ArticleId><ArticleId IdType="pii">medicina57121337</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Chi&#xf2; A., Moglia C., Canosa A., Manera U., Vasta R., Brunetti M., Barberis M., Corrado L., D&#x2019;Alfonso S., Bersano E., et al. Cognitive impairment across ALS clinical stages in a population-based cohort. Neurology. 2019;93:e984&#x2013;e994. doi: 10.1212/WNL.0000000000008063.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000008063</ArticleId><ArticleId IdType="pmc">PMC6745732</ArticleId><ArticleId IdType="pubmed">31409738</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu L., Liu T., Liu L., Yao X., Chen L., Fan D., Zhan S., Wang S. Global variation in prevalence and incidence of amyotrophic lateral sclerosis: A systematic review and meta-analysis. J. Neurol. 2019;267:944&#x2013;953. doi: 10.1007/s00415-019-09652-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-019-09652-y</ArticleId><ArticleId IdType="pubmed">31797084</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller R.G., Mitchell J.D., Moore D.H. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND) Cochrane Database Syst. Rev. 2012;2012:CD001447. doi: 10.1002/14651858.CD001447.pub3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD001447.pub3</ArticleId><ArticleId IdType="pmc">PMC7055506</ArticleId><ArticleId IdType="pubmed">22419278</ArticleId></ArticleIdList></Reference><Reference><Citation>Abe K., Aoki M., Tsuji S., Itoyama Y., Sobue G., Togo M., Hamada C., Tanaka M., Akimoto M., Nakamura K., et al. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: A randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2017;16:505&#x2013;512. doi: 10.1016/S1474-4422(17)30115-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(17)30115-1</ArticleId><ArticleId IdType="pubmed">28522181</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor J.P., Brown R.H., Jr., Cleveland D.W. Decoding ALS: From genes to mechanism. Nature. 2016;539:197&#x2013;206. doi: 10.1038/nature20413.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature20413</ArticleId><ArticleId IdType="pmc">PMC5585017</ArticleId><ArticleId IdType="pubmed">27830784</ArticleId></ArticleIdList></Reference><Reference><Citation>van Es M.A., Hardiman O., Chio A., Al-Chalabi A., Pasterkamp R.J., Veldink J.H., van den Berg L.H. Amyotrophic lateral sclerosis. Lancet. 2017;390:2084&#x2013;2098. doi: 10.1016/S0140-6736(17)31287-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(17)31287-4</ArticleId><ArticleId IdType="pubmed">28552366</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Chalabi A., Hardiman O. The epidemiology of ALS: A conspiracy of genes, environment and time. Nat. Rev. Neurol. 2013;9:617&#x2013;628. doi: 10.1038/nrneurol.2013.203.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2013.203</ArticleId><ArticleId IdType="pubmed">24126629</ArticleId></ArticleIdList></Reference><Reference><Citation>Zou Z.-Y., Zhou Z.-R., Che C.-H., Liu C.-Y., He R.-L., Huang H.-P. Genetic epidemiology of amyotrophic lateral sclerosis: A systematic review and meta-analysis. J. Neurol. Neurosurg. Psychiatry. 2017;88:540&#x2013;549. doi: 10.1136/jnnp-2016-315018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2016-315018</ArticleId><ArticleId IdType="pubmed">28057713</ArticleId></ArticleIdList></Reference><Reference><Citation>van Rheenen W., Registry P., Shatunov A., Dekker A.M., McLaughlin R.L., Diekstra F.P., Pulit S.L., van der Spek R.A., V&#xf5;sa U., de Jong S., et al. Genome-wide association analyses identify new risk variants and the genetic architecture of amyotrophic lateral sclerosis. Nat. Genet. 2016;48:1043&#x2013;1048. doi: 10.1038/ng.3622.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.3622</ArticleId><ArticleId IdType="pmc">PMC5556360</ArticleId><ArticleId IdType="pubmed">27455348</ArticleId></ArticleIdList></Reference><Reference><Citation>Montague P., McCallion A.S., Davies R.W., Griffiths I.R. Myelin-Associated Oligodendrocytic Basic Protein: A Family of Abundant CNS Myelin Proteins in Search of a Function. Dev. Neurosci. 2006;28:479&#x2013;487. doi: 10.1159/000095110.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000095110</ArticleId><ArticleId IdType="pubmed">17028425</ArticleId></ArticleIdList></Reference><Reference><Citation>Dulamea A.O. Role of Oligodendrocyte Dysfunction in Demyelination, Remyelination and Neurodegeneration in Multiple Sclerosis. Towar. Anti-Adhes. Ther. Microb. Dis. 2017;958:91&#x2013;127. doi: 10.1007/978-3-319-47861-6_7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-3-319-47861-6_7</ArticleId><ArticleId IdType="pubmed">28093710</ArticleId></ArticleIdList></Reference><Reference><Citation>Nasrabady S.E., Rizvi B., Goldman J.E., Brickman A.M. White matter changes in Alzheimer&#x2019;s disease: A focus on myelin and oligodendrocytes. Acta Neuropathol. Commun. 2018;6:22. doi: 10.1186/s40478-018-0515-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-018-0515-3</ArticleId><ArticleId IdType="pmc">PMC5834839</ArticleId><ArticleId IdType="pubmed">29499767</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaye J.F., de Rosbo N.K., Mendel I., Flechter S., Hoffman M., Yust I., Ben-Nun A. The central nervous sytem-specific myelin oligodendrocytic basic protein (MOBP) is encephalitogenic and a potential target antigen in multiple sclerosis (MS) J. Neuroimmunol. 2000;102:189&#x2013;198. doi: 10.1016/S0165-5728(99)00168-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0165-5728(99)00168-X</ArticleId><ArticleId IdType="pubmed">10636488</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Q.-Y., Yu J.-T., Miao D., Ma X.-Y., Wang H.-F., Wang W., Tan L. An exploratory study on STX6, MOBP, MAPT, and EIF2AK3 and late-onset Alzheimer&#x2019;s disease. Neurobiol. Aging. 2013;34:1519.e13&#x2013;1519.e17. doi: 10.1016/j.neurobiolaging.2012.10.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2012.10.004</ArticleId><ArticleId IdType="pubmed">23116876</ArticleId></ArticleIdList></Reference><Reference><Citation>Holz A., Bielekova B., Martin R., Oldstone M.B.A. Myelin-Associated Oligodendrocytic Basic Protein: Identification of an Encephalitogenic Epitope and Association with Multiple Sclerosis. J. Immunol. 2000;164:1103&#x2013;1109. doi: 10.4049/jimmunol.164.2.1103.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.164.2.1103</ArticleId><ArticleId IdType="pubmed">10623862</ArticleId></ArticleIdList></Reference><Reference><Citation>Irwin D.J., McMillan C.T., Suh E., Powers J., Rascovsky K., Wood E.M., Toledo J.B., Arnold S.E., Lee V.M.-Y., Van Deerlin V.M., et al. Myelin oligodendrocyte basic protein and prognosis in behavioral-variant frontotemporal dementia. Neurology. 2014;83:502&#x2013;509. doi: 10.1212/WNL.0000000000000668.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000000668</ArticleId><ArticleId IdType="pmc">PMC4141997</ArticleId><ArticleId IdType="pubmed">24994843</ArticleId></ArticleIdList></Reference><Reference><Citation>H&#xf6;glinger G., Melhem N.M., Dickson D.W., Sleiman P.M.A., Wang L.-S., Klei L., Rademakers R., De Silva R., Litvan I., Riley D.E., et al. Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy. Nat. Genet. 2011;43:699&#x2013;705. doi: 10.1038/ng.859.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.859</ArticleId><ArticleId IdType="pmc">PMC3125476</ArticleId><ArticleId IdType="pubmed">21685912</ArticleId></ArticleIdList></Reference><Reference><Citation>Niebroj-Dobosz I., Rafa&#x142;owska J., Fidzia&#x144;ska A., Gadamski R., Grieb P. Myelin composition of spinal cord in a model of amyotrophic lateral sclerosis (ALS) in SOD1G93A transgenic rats. Folia Neuropathol. 2007;45:236&#x2013;241.</Citation><ArticleIdList><ArticleId IdType="pubmed">18176898</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou T., Ahmad T.K., Gozda K., Truong J., Kong J., Namaka M. Implications of white matter damage in amyotrophic lateral sclerosis. Mol. Med. Rep. 2017;16:4379&#x2013;4392. doi: 10.3892/mmr.2017.7186.</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/mmr.2017.7186</ArticleId><ArticleId IdType="pmc">PMC5646997</ArticleId><ArticleId IdType="pubmed">28791401</ArticleId></ArticleIdList></Reference><Reference><Citation>Philips T., Bento-Abreu A., Nonneman A., Haeck W., Staats K., Geelen V., Hersmus N., K&#xfc;sters B., Van Den Bosch L., Van Damme P., et al. Oligodendrocyte dysfunction in the pathogenesis of amyotrophic lateral sclerosis. Brain. 2013;136:471&#x2013;482. doi: 10.1093/brain/aws339.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/aws339</ArticleId><ArticleId IdType="pmc">PMC3572934</ArticleId><ArticleId IdType="pubmed">23378219</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang S.H., Li Y., Fukaya M., Lorenzini I., Cleveland D., Ostrow L., Rothstein J.D., Bergles D.E. Degeneration and impaired regeneration of gray matter oligodendrocytes in amyotrophic lateral sclerosis. Nat. Neurosci. 2013;16:571&#x2013;579. doi: 10.1038/nn.3357.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.3357</ArticleId><ArticleId IdType="pmc">PMC3637847</ArticleId><ArticleId IdType="pubmed">23542689</ArticleId></ArticleIdList></Reference><Reference><Citation>Von Elm E., Altman D.G., Egger M., Pocock S.J., Gotzsche P.C., Vandenbroucke J.P., STROBE Initiative The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for reporting observational studies. Int. J. Surg. 2014;12:1495&#x2013;1499. doi: 10.1016/j.ijsu.2014.07.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijsu.2014.07.013</ArticleId><ArticleId IdType="pubmed">25046131</ArticleId></ArticleIdList></Reference><Reference><Citation>Siokas V., Karampinis E., Aloizou A.-M., Mentis A.-F.A., Liakos P., Papadimitriou D., Liampas I., Nasios G., Bogdanos D.P., Hadjigeorgiou G.M., et al. CYP1A2 rs762551 polymorphism and risk for amyotrophic lateral sclerosis. Neurol. Sci. 2021;42:175&#x2013;182. doi: 10.1007/s10072-020-04535-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10072-020-04535-x</ArticleId><ArticleId IdType="pubmed">32592103</ArticleId></ArticleIdList></Reference><Reference><Citation>Dardiotis E., Karampinis E., Siokas V., Aloizou A.-M., Rikos D., Ralli S., Papadimitriou D., Bogdanos D., Hadjigeorgiou G.M. ERCC6L2 rs591486 polymorphism and risk for amyotrophic lateral sclerosis in Greek population. Neurol. Sci. 2019;40:1237&#x2013;1244. doi: 10.1007/s10072-019-03825-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10072-019-03825-3</ArticleId><ArticleId IdType="pubmed">30879219</ArticleId></ArticleIdList></Reference><Reference><Citation>Ludolph A., Drory V., Hardiman O., Nakano I., Ravits J., Robberecht W., Shefner J. WFN Research Group On ALS/MND A revision of the El Escorial criteria&#x2014;2015. Amyotroph. Lateral Scler. Front. Degener. 2015;16:291&#x2013;292. doi: 10.3109/21678421.2015.1049183.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2015.1049183</ArticleId><ArticleId IdType="pubmed">26121170</ArticleId></ArticleIdList></Reference><Reference><Citation>Dardiotis E., Siokas V., Zafeiridis T., Paterakis K., Tsivgoulis G., Dardioti M., Grigoriadis S., Simeonidou C., Deretzi G., Zintzaras E., et al. Integrins AV and B8 Gene Polymorphisms and Risk for Intracerebral Hemorrhage in Greek and Polish Populations. Neuromol. Med. 2016;19:69&#x2013;80. doi: 10.1007/s12017-016-8429-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12017-016-8429-3</ArticleId><ArticleId IdType="pubmed">27476161</ArticleId></ArticleIdList></Reference><Reference><Citation>Siokas V., Aslanidou P., Aloizou A.-M., Peristeri E., Stamati P., Liampas I., Arseniou S., Drakoulis N., Aschner M., Tsatsakis A., et al. Does the CD33 rs3865444 Polymorphism Confer Susceptibility to Alzheimer&#x2019;s Disease? J. Mol. Neurosci. 2020;70:851&#x2013;860. doi: 10.1007/s12031-020-01507-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12031-020-01507-w</ArticleId><ArticleId IdType="pubmed">32088842</ArticleId></ArticleIdList></Reference><Reference><Citation>Siokas V., Kardaras D., Aloizou A.-M., Liampas I., Papageorgiou E., Drakoulis N., Tsatsakis A., Mitsias P.D., Hadjigeorgiou G.M., Tsironi E.E., et al. CYP1A2 rs762551 and ADORA2A rs5760423 Polymorphisms in Patients with Blepharospasm. J. Mol. Neurosci. 2020;70:1370&#x2013;1375. doi: 10.1007/s12031-020-01553-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12031-020-01553-4</ArticleId><ArticleId IdType="pubmed">32424513</ArticleId></ArticleIdList></Reference><Reference><Citation>Skol A.D., Scott L.J., Abecasis G., Boehnke M. Joint analysis is more efficient than replication-based analysis for two-stage genome-wide association studies. Nat. Genet. 2006;38:209&#x2013;213. doi: 10.1038/ng1706.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng1706</ArticleId><ArticleId IdType="pubmed">16415888</ArticleId></ArticleIdList></Reference><Reference><Citation>Sol&#xe9; X., Guin&#xf3; E., Valls J., Iniesta R., Moreno V. SNPStats: A web tool for the analysis of association studies. Bioinformatics. 2006;22:1928&#x2013;1929. doi: 10.1093/bioinformatics/btl268.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btl268</ArticleId><ArticleId IdType="pubmed">16720584</ArticleId></ArticleIdList></Reference><Reference><Citation>Zintzaras E., Santos M. Estimating the mode of inheritance in genetic association studies of qualitative traits based on the degree of dominance index. BMC Med. Res. Methodol. 2011;11:171. doi: 10.1186/1471-2288-11-171.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2288-11-171</ArticleId><ArticleId IdType="pmc">PMC3299619</ArticleId><ArticleId IdType="pubmed">22188898</ArticleId></ArticleIdList></Reference><Reference><Citation>Yates A.D., Achuthan P., Akanni W., Allen J., Alvarez-Jarreta J., Amode M.R., Armean I.M., Azov A.G., Bennett R., Bhai J., et al. Ensembl 2020. Nucleic Acids Res. 2020;48:D682&#x2013;D688. doi: 10.1093/nar/gkz966.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkz966</ArticleId><ArticleId IdType="pmc">PMC7145704</ArticleId><ArticleId IdType="pubmed">31691826</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Eijk R.P.A., Eijkemans M.J.C., Nikolakopoulos S., Jansen M.D., Westeneng H.-J., Van Eijk K.R., Van Der Spek R.A.A., Van Vugt J.J.F.A., Piepers S., Groeneveld G.-J., et al. Pharmacogenetic interactions in amyotrophic lateral sclerosis: A step closer to a cure? Pharmacogenom. J. 2020;20:220&#x2013;226. doi: 10.1038/s41397-019-0111-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41397-019-0111-3</ArticleId><ArticleId IdType="pubmed">31624333</ArticleId></ArticleIdList></Reference><Reference><Citation>Montague P., Kirkham D., McCallion A.S., Davies R., Kennedy P.G., Klugmann M., Nave K.-A., Griffiths I.R. Reduced levels of a specific myelin-associated oligodendrocytic basic protein isoform in shiverer myelin. Dev. Neurosci. 1999;21:36&#x2013;42. doi: 10.1159/000017364.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000017364</ArticleId><ArticleId IdType="pubmed">10077700</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamamoto Y., Yoshikawa H., Nagano S., Kondoh G., Sadahiro S., Gotow T., Yanagihara T., Sakoda S. Myelin-associated oligodendrocytic basic protein is essential for normal arrangement of the radial component in central nervous system myelin. Eur. J. Neurosci. 1999;11:847&#x2013;855. doi: 10.1046/j.1460-9568.1999.00490.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1460-9568.1999.00490.x</ArticleId><ArticleId IdType="pubmed">10103078</ArticleId></ArticleIdList></Reference><Reference><Citation>Nonneman A., Robberecht W., Bosch L.V.D. The role of oligodendroglial dysfunction in amyotrophic lateral sclerosis. Neurodegener. Dis. Manag. 2014;4:223&#x2013;239. doi: 10.2217/nmt.14.21.</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/nmt.14.21</ArticleId><ArticleId IdType="pubmed">25095817</ArticleId></ArticleIdList></Reference><Reference><Citation>Kon T., Tanji K., Mori F., Kimura A., Kakita A., Wakabayashi K. Immunoreactivity of myelin-associated oligodendrocytic basic protein in Lewy bodies. Neuropathology. 2019;39:279&#x2013;285. doi: 10.1111/neup.12564.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/neup.12564</ArticleId><ArticleId IdType="pubmed">31183926</ArticleId></ArticleIdList></Reference><Reference><Citation>Siokas V., Aloizou A., Liampas I., Bakirtzis C., Tsouris Z., Sgantzos M., Liakos P., Bogdanos D.P., Hadjigeorgiou G.M., Dardiotis E. Myelin-associated oligodendrocyte basic protein rs616147 polymorphism as a risk factor for Parkinson&#x2019;s disease. Acta Neurol. Scand. 2021 doi: 10.1111/ane.13538.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ane.13538</ArticleId><ArticleId IdType="pubmed">34694630</ArticleId></ArticleIdList></Reference><Reference><Citation>McMillan C.T., Toledo J.B., Avants B.B., Cook P.A., Wood E.M., Suh E., Irwin D.J., Powers J., Olm C., Elman L., et al. Genetic and neuroanatomic associations in sporadic frontotemporal lobar degeneration. Neurobiol. Aging. 2014;35:1473&#x2013;1482. doi: 10.1016/j.neurobiolaging.2013.11.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2013.11.029</ArticleId><ArticleId IdType="pmc">PMC3961542</ArticleId><ArticleId IdType="pubmed">24373676</ArticleId></ArticleIdList></Reference><Reference><Citation>Allen M., Burgess J.D., Ballard T., Serie D., Wang X., Younkin C.S., Sun Z., Kouri N., Baheti S., Wang C., et al. Gene expression, methylation and neuropathology correlations at progressive supranuclear palsy risk loci. Acta Neuropathol. 2016;132:197&#x2013;211. doi: 10.1007/s00401-016-1576-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-016-1576-7</ArticleId><ArticleId IdType="pmc">PMC4947429</ArticleId><ArticleId IdType="pubmed">27115769</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanchez-Contreras M.Y., Kouri N., Cook C.N., Serie D.J., Heckman M.G., Finch N.A., Caselli R.J., Uitti R.J., Wszolek Z.K., Graff-Radford N., et al. Replication of progressive supranuclear palsy genome-wide association study identifies SLCO1A2 and DUSP10 as new susceptibility loci. Mol. Neurodegener. 2018;13:37. doi: 10.1186/s13024-018-0267-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-018-0267-3</ArticleId><ArticleId IdType="pmc">PMC6038352</ArticleId><ArticleId IdType="pubmed">29986742</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Z., Chen J.A., Shatunov A., Jones A., Bs S.N.K., Huang A.Y., Lawrence L., Lowe J.K., Lewis C., Payan C.A.M., et al. Genome-wide survey of copy number variants finds MAPT duplications in progressive supranuclear palsy. Mov. Disord. 2019;34:1049&#x2013;1059. doi: 10.1002/mds.27702.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.27702</ArticleId><ArticleId IdType="pubmed">31059154</ArticleId></ArticleIdList></Reference><Reference><Citation>Yokoyama J.S., International FTD-Genomics Consortium (IFGC) Karch C., Fan C.C., Bonham L.W., Kouri N., Ross O., Rademakers R., Kim J., Wang Y., et al. Shared genetic risk between corticobasal degeneration, progressive supranuclear palsy, and frontotemporal dementia. Acta Neuropathol. 2017;133:825&#x2013;837. doi: 10.1007/s00401-017-1693-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-017-1693-y</ArticleId><ArticleId IdType="pmc">PMC5429027</ArticleId><ArticleId IdType="pubmed">28271184</ArticleId></ArticleIdList></Reference><Reference><Citation>Kouri N., Ross O., Dombroski B., Younkin C.S., Serie D.J., Soto-Ortolaza A., Baker M., Finch N.C.A., Yoon H., Kim J., et al. Genome-wide association study of corticobasal degeneration identifies risk variants shared with progressive supranuclear palsy. Nat. Commun. 2015;6:7247. doi: 10.1038/ncomms8247.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms8247</ArticleId><ArticleId IdType="pmc">PMC4469997</ArticleId><ArticleId IdType="pubmed">26077951</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrer I., Benito P.A., Zelaya M.V., Aguirre M.E.E., Carmona M., Aus&#xed;n K., Lach&#xe9;n-Montes M., Fern&#xe1;ndez-Irigoyen J., Santamar&#xed;a E., Del Rio J.A. Familial globular glial tauopathy linked to MAPT mutations: Molecular neuropathology and seeding capacity of a prototypical mixed neuronal and glial tauopathy. Acta Neuropathol. 2020;139:735&#x2013;771. doi: 10.1007/s00401-019-02122-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-019-02122-9</ArticleId><ArticleId IdType="pmc">PMC7096369</ArticleId><ArticleId IdType="pubmed">31907603</ArticleId></ArticleIdList></Reference><Reference><Citation>Bettencourt C., Foti S.C., Miki Y., Bot&#xed;a J.A., Chatterjee A., Warner T.T., Revesz T., Lashley T., Balazs R., Vire E., et al. White matter DNA methylation profiling reveals deregulation of HIP1, LMAN2, MOBP, and other loci in multiple system atrophy. Acta Neuropathol. 2020;139:135&#x2013;156. doi: 10.1007/s00401-019-02074-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-019-02074-0</ArticleId><ArticleId IdType="pmc">PMC6942018</ArticleId><ArticleId IdType="pubmed">31535203</ArticleId></ArticleIdList></Reference><Reference><Citation>Belbasis L., Bellou V., Evangelou E. Environmental Risk Factors and Amyotrophic Lateral Sclerosis: An Umbrella Review and Critical Assessment of Current Evidence from Systematic Reviews and Meta-Analyses of Observational Studies. Neuroepidemiology. 2016;46:96&#x2013;105. doi: 10.1159/000443146.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000443146</ArticleId><ArticleId IdType="pubmed">26731747</ArticleId></ArticleIdList></Reference><Reference><Citation>Liampas I., Chlinos A., Siokas V., Brotis A., Dardiotis E. Assessment of the reporting quality of RCTs for novel oral anticoagulants in venous thromboembolic disease based on the CONSORT statement. J. Thromb. Thrombolysis. 2019;48:542&#x2013;553. doi: 10.1007/s11239-019-01931-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11239-019-01931-9</ArticleId><ArticleId IdType="pubmed">31401718</ArticleId></ArticleIdList></Reference><Reference><Citation>Kodounis M., Liampas I.N., Constantinidis T.S., Siokas V., Mentis A.-F.A., Aloizou A.-M., Xiromerisiou G., Zintzaras E., Hadjigeorgiou G.M., Dardiotis E. Assessment of the reporting quality of double-blind RCTs for ischemic stroke based on the CONSORT statement. J. Neurol. Sci. 2020;415:116938. doi: 10.1016/j.jns.2020.116938.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2020.116938</ArticleId><ArticleId IdType="pubmed">32492609</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>